Ken Griffin Amylyx Pharmaceuticals, Inc. Transaction History

Citadel Advisors LLC

$559 Billion
Q4 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Amylyx Pharmaceuticals, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 135,000 shares of AMLX stock, worth $661,500. This represents 0.0% of its overall portfolio holdings.

Number of Shares

135,000

Previous 89,300 51.18%

Holding current value

$661,500

Previous $289,000 75.78%

% of portfolio

0.0%

Previous 0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$2.94 - $7.03 $209,163 - $500,142	71,144 Added 3.75%	1,970,704 $7.43 Million
Q3 2024 Nov 14, 2024	BUY	$1.65 - $3.24 $915,324 - $1.8 Million	554,742 Added 41.25%	1,899,560 $6.15 Million
Q2 2024 Aug 14, 2024	BUY	$1.62 - $2.71 $23,383 - $39,116	14,434 Added 1.08%	1,344,818 $2.56 Million
Q1 2024 May 15, 2024	SELL	$2.71 - $19.57 $2.47 Million - $17.8 Million	-910,501 Reduced 40.63%	1,330,384 $3.78 Million
Q4 2023 Feb 14, 2024	BUY	$12.07 - $18.46 $12.2 Million - $18.7 Million	1,013,941 Added 82.64%	2,240,885 $33 Million
Q3 2023 Nov 14, 2023	BUY	$18.08 - $23.45 $7.48 Million - $9.7 Million	413,619 Added 50.86%	1,226,944 $22.5 Million
Q2 2023 Aug 14, 2023	BUY	$20.98 - $31.42 $12.3 Million - $18.4 Million	584,419 Added 255.31%	813,325 $17.5 Million
Q1 2023 May 15, 2023	BUY	$27.71 - $40.93 $4.77 Million - $7.05 Million	172,149 Added 303.31%	228,906 $6.72 Million
Q4 2022 Feb 14, 2023	SELL	$29.75 - $39.26 $22.3 Million - $29.4 Million	-750,073 Reduced 92.97%	56,757 $2.1 Million
Q3 2022 Nov 14, 2022	BUY	$17.15 - $30.92 $899,002 - $1.62 Million	52,420 Added 6.95%	806,830 $22.7 Million

Others Institutions Holding AMLX

# of Institutions

141

Shares Held

53.7M

Call Options Held

290K

Put Options Held

205K

View Full List

About Amylyx Pharmaceuticals, Inc.

Ticker AMLX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,533,200
Market Cap $287M
Description
Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment...

More about AMLX

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account